Stockreport

Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress

Axovant Gene Therapies Ltd.  (AXGT) 
Last axovant gene therapies ltd. earnings: 2/10 06:00 am Check Earnings Report
PDF Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRIAXO-AAV [Read more]